Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma

Pavlin, Darja; Čemažar, Maja; Kamenšek, Urška; Tozon, Nataša; Pogačnik, A.; Serša, Gregor

doi:10.4161/cbt.8.22.9734

Cited by 55 publications

(50 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antitumor effectiveness of intratumoral IL-12 electrogene therapy was demonstrated also in other types of cancer, such as colon carcinoma, renal cancer, lymphoma, breast carcinoma and sarcoma mouse tumor models [75][76][77][78][79][80]. Treatment of CT26 colon carcinoma tumors with 3 times repeated intratumoral IL-12 electrogene therapy resulted in significant inhibition of tumor growth.…”

Section: Preclinical Studies With Il-12 Electro-gene Therapymentioning

confidence: 96%

“…In the same study, 3 times repeated intramuscular IL-12 electrotransfer resulted in 27% SA-1 and 14% LPB subcutaneous sarcoma tumor cures. The effects of peritumoral and intratumoral IL-12 electrogene therapy were compared on the same tumor model, the SA-1 sarcoma [79]. This was the first study which addressed the antitumor effectiveness of IL-12 electrogene therapy applied to skin in the vicinity of established tumors -peritumoral electrogene therapy.…”

Section: Preclinical Studies With Il-12 Electro-gene Therapymentioning

confidence: 99%

See 1 more Smart Citation

Cancer Electrogene Therapy with Interleukin-12

Čemažar¹,

Jarm²,

Serša

2010

CGT

Self Cite

View full text Add to dashboard Cite

Electrogene therapy combines administration of plasmid DNA into tissue followed by local application of electric pulses. In electrogene therapy with interleukin-12 (IL-12), different routes of administration, different doses of plasmid DNA and different protocols for delivery of electric pulses were evaluated in numerous preclinical studies. Antitumor effectiveness was tested in different types of primary tumors, distantly growing tumors and induced metastases. Intratumoral IL-12 electrogene therapy has been proved to be very effective in local tumor control, having also a systemic effect. Intramuscular and peritumoral IL-12 electrogene therapy had also a pronounced systemic effect and when combined with other treatment strategies resulted in tumor cures. Antitumor effectiveness of IL-12 electrogene therapy is due to the induction of adaptive immunity and innate resistance and anti-angiogenic action. Translation of preclinical studies into clinical trials in human and veterinary oncology has started with encouraging results that would hopefully lead to further investigation of this therapy, also in combination with other cancer treatment modalities.

show abstract

Section: Preclinical Studies With Il-12 Electro-gene Therapymentioning

confidence: 96%

Section: Preclinical Studies With Il-12 Electro-gene Therapymentioning

confidence: 99%

Cancer Electrogene Therapy with Interleukin-12

Čemažar¹,

Jarm²,

Serša

2010

CGT

Self Cite

View full text Add to dashboard Cite

show abstract

“…These findings are consistent with previously documented effects of IL-12. This approach has similarly been successfully applied to a murine model of fibrosarcoma (66).…”

Section: Preclinical Studies Investigating the Anti-tumor Therapeuticmentioning

confidence: 99%

Interleukin 12: Stumbling Blocks and Stepping Stones to Effective Anti-Tumor Therapy

Pegram¹,

Chekmasova²,

Imperato³

et al. 2012

Advancements in Tumor Immunotherapy and Cancer Vaccines

View full text Add to dashboard Cite

“…In vivo tumor regressions have been durable and treated animals may be resistant to tumor reimplantation suggesting that intratumoral electroporation of pIL-12 DNA induces memory immune responses in these models [47,48]. Although intramuscular electroporation of pIL-12 has been examined, intratumoral therapy leads to more elaboration of cytokines in the tumor microenvironment and higher rates of tumor regressions [49,50].…”

Section: Electroporation Of Il-12 Dna To Enhance Therapeutic Deliverymentioning

confidence: 99%

“…A first-in-human Phase I trial of tavo electroporation A phase I trial was conducted at the Moffitt Cancer Center from December 2004 to February 2007 [49]. Patients had metastatic melanoma with accessible cutaneous disease that was surgically unresectable.…”

Section: Preclinical Studiesmentioning

confidence: 99%

Melanoma Treatment with Intratumoral Electroporation of Tavokinogene Telseplasmid (pIL-12, Tavokinogene Telseplasmid)

Canton¹,

Shirley²,

Wright³

et al. 2017

Immunotherapy

View full text Add to dashboard Cite

Tumors evade detection and/or clearance by the immune system via multiple mechanisms. IL-12 is a potent immunomodulatory cytokine that plays a central role in immune priming. However, systemic delivery of IL-12 can result in life-threatening toxicity and therefore has shown limited efficacy at doses that can be safely administered. We developed an electroporation technique to produce highly localized IL-12 expression within tumors leading to regression of both treated and untreated lesions in animal models and in patients with a favorable safety profile. Furthermore, intratumoral tavokinogene telseplasmid electroporation can drive cellular immune responses, converting ‘cold’ tumors into ‘hot’ tumors. Clinical trials are ongoing to determine whether intratumoral tavokinogene telseplasmid electroporation synergizes with checkpoint blockade therapy in immunologically cold tumors predicted not to respond to PD-1 antibody monotherapy.

show abstract

Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma

Cited by 55 publications

References 36 publications

Cancer Electrogene Therapy with Interleukin-12

Cancer Electrogene Therapy with Interleukin-12

Interleukin 12: Stumbling Blocks and Stepping Stones to Effective Anti-Tumor Therapy

Melanoma Treatment with Intratumoral Electroporation of Tavokinogene Telseplasmid (pIL-12, Tavokinogene Telseplasmid)

Contact Info

Product

Resources

About